Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareSource Actemra Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentCareSourcePolicy 4588458

    Actemra intravenous and subcutaneous coverage

    Customize your policy alerts

    Sign up for CareSource Policy 4588458 alerts

    Get alerted when Policy 4588458 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization requirements for Actemra intravenous, Actemra ACTPEN, and Actemra subcutaneous products for FDA-approved indications and specified criteria-based uses.

    Policy Summary
    PayerCareSource
    PolicyActemra intravenous and subcutaneous coverage
    Policy CodePolicy 4588458
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for Actemra intravenous, Actemra ACTPEN, or Actemra subcutaneous products and include the diagnosis, concurrent medications, and previous drugs tried.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Actemra products affected
    Plan yearCoverage approval duration
    YesPrerequisite therapy required
    NoPart B prerequisite

    Product-Specific Coverage Criteria

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Rheumatoid arthritis initial therapy

    Covered when either pathway is met.

    Rheumatoid arthritis: Patient has rheumatoid arthritis and has tried one qualifying drug (Enbrel, a preferred adalimumab product, Rinvoq, or tofacitinib/tofacitinib XR; specified alternative biologics or a non-preferred adalimumab product also count), or has heart failure or a previously treated lymphoproliferative disorder.

    PJIA initial therapy

    Covered when either pathway is met.

    Polyarticular juvenile idiopathic arthritis: Patient has PJIA and has tried one qualifying drug (Enbrel, Rinvoq, tofacitinib, or a preferred adalimumab product; specified alternative therapies or a non-preferred adalimumab product also count), or has heart failure or a previously treated lymphoproliferative disorder.

    Other covered indications

    Covered when the applicable indication criteria are met.

    Other covered indications: Systemic-onset JIA; giant cell arteritis with a systemic corticosteroid tried, currently used, or contraindicated; or interstitial lung disease associated with systemic sclerosis with elevated acute phase reactants and diagnosis confirmed by high-resolution computed tomography.

    Alunbrig initial therapy

    Covered when the applicable indication pathway is met.

    Alunbrig indications: ALK-positive advanced or metastatic NSCLC detected by an approved test; ALK-positive advanced, recurrent, or metastatic inflammatory myofibroblastic tumor or inoperable tumor; or ALK-positive anaplastic large cell lymphoma.

    Anktiva initial therapy

    All criteria must be met.

    Anktiva: High-risk BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, and use in combination with BCG.

    Arcalyst initial therapy

    Meet the applicable indication pathway.

    Arcalyst initial indications: DIRA requires weight at least 10 kg, biallelic pathogenic IL1RN variants, and clinical benefit with anakinra; recurrent pericarditis must be recurrent; or CAPS meets applicable coverage requirements.

    Arcalyst continuation therapy

    Continuation requires response.

    Arcalyst continuation: Patient had a positive response to Arcalyst therapy.

    Arikayce initial therapy

    All criteria must be met.

    Initial MAC lung disease: Positive MAC sputum culture, amikacin-susceptible isolate, and use with a background multidrug regimen.

    Arikayce continuation therapy

    All criteria must be met, including one culture-status alternative.

    Continuation MAC lung disease: Arikayce is used with a background multidrug regimen and the patient either has not achieved negative MAC sputum cultures or achieved negative cultures for less than 12 months.

    Aubagio and Avonex coverage

    Coverage is for relapsing multiple sclerosis.

    Aubagio and Avonex: Patient has relapsing MS, including clinically isolated syndrome, relapsing-remitting disease, or active secondary progressive disease; concurrent use with another MS disease-modifying agent is excluded.

    Augtyro coverage

    Meet one applicable indication pathway.

    Augtyro indications: Locally advanced or metastatic ROS1-positive NSCLC confirmed by an approved test; locally advanced, metastatic, or severely morbid-to-resect NTRK fusion-positive solid tumor; or NTRK fusion-positive pediatric diffuse high-grade glioma used as adjuvant therapy or for recurrent/progressive disease.

    Avmapki-Fakzynja coverage

    All criteria must be met.

    Avmapki-Fakzynja: Recurrent low-grade serous ovarian, fallopian tube, or primary peritoneal cancer; KRAS mutation; and at least one prior systemic therapy.

    Avmapki-fakzynja

    All criteria must be met.

    Avmapki-fakzynja: Recurrent low-grade serous ovarian, fallopian tube, or primary peritoneal cancer with a KRAS mutation and at least one prior systemic therapy.

    Ayvakit

    Meet one applicable disease pathway.

    Ayvakit: GIST with PDGFRA exon 18 mutation or after two listed prior therapies; PDGFRA D842V-positive myeloid/lymphoid neoplasm with eosinophilia; or systemic mastocytosis meeting the platelet-count and subtype criteria.Systemic mastocytosis platelet count >=50,000/mcL

    Balversa

    Meet the applicable disease and molecular criteria.

    Balversa: Susceptible FGFR3 alteration with progression during or after applicable prior therapy; locally advanced, recurrent, or metastatic FGFR-altered pancreatic adenocarcinoma used as subsequent single-agent therapy; or metastatic FGFR-altered NSCLC.

    Benlysta and Benlysta IV

    Meet the applicable lupus indication criteria.

    Benlysta and Benlysta IV: Biopsy-confirmed lupus nephritis with concurrent immunosuppressive therapy, or autoantibody-positive SLE with concurrent standard therapy. Initial age is at least 5 years; lupus nephritis continuation also requires response.

    Bexarotene topical

    Covered for the specified lymphoma indications.

    Topical bexarotene: Cutaneous T-cell lymphoma with cutaneous manifestations or lesions; smoldering symptomatic adult T-cell leukemia/lymphoma treated first line; or primary cutaneous marginal-zone or follicle-center B-cell lymphoma treated with skin-directed therapy.

    Bizengri

    Meet one applicable cancer pathway.

    Bizengri: Advanced, unresectable, or metastatic NRG1 gene-fusion-positive cholangiocarcinoma; or corresponding NRG1-positive NSCLC or pancreatic adenocarcinoma after at least one systemic regimen.

    Blenrep

    All criteria must be met.

    Blenrep: At least one prior proteasome inhibitor and one prior immunomodulatory drug, with planned combination use with bortezomib and dexamethasone.Age >=18 years

    Boniva Injection

    Postmenopausal osteoporosis plus at least one qualifying criterion is required.

    Boniva Injection: T-score at or below -2.5; osteoporotic or fragility fracture; osteopenia with high fracture risk and inadequate oral bisphosphonate response after 12 months; fracture or intolerance on oral therapy; inability to take oral therapy; or prior IV bisphosphonate.

    Bosentan or Ambrisentan

    Meet the applicable PAH or CTEPH pathway.

    Bosentan or Ambrisentan: WHO Group 1 PAH confirmed by right-heart catheterization; or CTEPH treated with bosentan after an Adempas trial, Adempas contraindication, or current bosentan therapy.

    Bosulif

    Meet one applicable hematologic malignancy pathway.

    Bosulif: Philadelphia chromosome-positive or BCR::ABL1-positive CML; Philadelphia chromosome-positive ALL after at least one other TKI; or qualifying myeloid/lymphoid neoplasm with eosinophilia.

    Bosentan/ambrisentan

    Meet the applicable diagnosis, testing, prescriber, and prerequisite criteria.

    Bosentan/ambrisentan: WHO Group 1 PAH confirmed by right-heart catheterization with cardiologist or pulmonologist involvement, or CTEPH treated with bosentan after the specified Adempas prerequisite or current bosentan use.

    Bosulif

    Meet the applicable diagnosis and age or prior-treatment criteria.

    Bosulif: CML with Philadelphia chromosome-positive or BCR::ABL1-positive disease; Ph-positive ALL after another TKI; or myeloid/lymphoid neoplasm with eosinophilia.Age >=15 years generally; >=18 years for myeloid/lymphoid neoplasms with eosinophilia

    Braftovi

    Document diagnosis, mutation status, and required regimen.

    Braftovi: BRAF V600-mutated advanced melanoma; BRAF V600E colorectal or rectal cancer with the required combination regimen; BRAF V600E recurrent/advanced/metastatic NSCLC with Mektovi; or BRAF V600E advanced/metastatic appendiceal adenocarcinoma with Erbitux or Vectibix.Age >=18 years

    Briumvi

    All criteria must be met.

    Briumvi: Relapsing multiple sclerosis, age at least 18 years, neurologist or MS specialist involvement, and no concurrent MS disease-modifying agent.

    Brukinsa

    Meet the malignancy-specific criteria.

    Brukinsa: Covered follicular, CLL/SLL, mantle-cell, marginal-zone, Waldenstrom/lymphoplasmacytic, hairy-cell, or primary CNS lymphoma pathway with the required prior systemic therapy or combination treatment.Age >=18 years

    Cinryze

    Meet the applicable HAE diagnostic or response criteria.

    Cinryze: Type I or II HAE with baseline functional C1-INH below 50% of normal and low C4; established type I or II HAE with favorable response; or HAE with normal C1-INH.

    Cablivi

    All criteria must be met.

    Cablivi: Acquired TTP treatment was initiated inpatient with plasma exchange; patient is receiving at least one immunosuppressive therapy; and prior Cablivi exposure was no more than two courses.Age >=12 years

    Cabometyx

    Meet the indication-specific criteria.

    Cabometyx: Qualifying renal, hepatic, bone, thyroid, endometrial, GIST, RET-positive NSCLC, or well-differentiated pancreatic or extra-pancreatic neuroendocrine tumor pathway with required disease status, molecular findings, and prior therapy.

    Calquence

    Meet the applicable malignancy and treatment-history criteria.

    Calquence: CLL/SLL; mantle-cell lymphoma with the required prior regimen, ineligibility, or rituximab combination; marginal-zone lymphoma after one systemic regimen; or Waldenstrom/lymphoplasmacytic lymphoma after one systemic regimen.

    Camzyos initial and continuation therapy

    Initial and continuation criteria must be met as applicable.

    Initial therapy: Symptomatic obstructive HCM; NYHA class II or III heart failure; specified LV hypertrophy; and peak LV outflow tract gradient at least 50 mmHg.
    Continuation therapy: At least 8 months established therapy, current LVEF at least 50%, and objective benefit or stabilization/improvement of an HCM symptom.

    Caprelsa

    Covered for FDA-approved and specified medically accepted indications.

    Caprelsa: A qualifying FDA-approved or medically accepted indication, including differentiated thyroid cancer such as papillary, follicular, or oncocytic thyroid cancer.

    Deferasirox initial and continuation therapy

    Meet the applicable initial or continuation criteria.

    Deferasirox: Qualifying iron-overload condition with ferritin greater than 1,000 mcg/L before therapy; or non-transfusion-dependent thalassemia with ferritin greater than 300 mcg/L. Continuation requires physician-confirmed benefit.

    Deferiprone iron overload

    Coverage is for qualifying chronic transfusion-related iron overload.

    Deferiprone: Chronic transfusion-related iron overload due to thalassemia syndrome, sickle cell disease, or another anemia. Continuation requires documented benefit.

    Diacomit Dravet syndrome

    Initial or continuation criteria must be met.

    Initial therapy: Age at least 6 months, Dravet syndrome, and concomitant clobazam or inability to take clobazam because of adverse events.
    Continuation therapy: Patient is responding to Diacomit therapy.

    Doptelet thrombocytopenia

    Coverage depends on indication and treatment phase.

    Chronic liver disease thrombocytopenia: Doptelet tablets, platelet count below 50 x 10^9/L, bleeding risk, and prior therapy failure or splenectomy.
    Chronic ITP continuation: Beneficial clinical response and ongoing risk of bleeding complications.

    Droxidopa NOH

    All criteria must be met.

    Neurogenic orthostatic hypotension: Age at least 18 years and symptomatic NOH due to primary autonomic failure, dopamine beta-hydroxylase deficiency, or non-diabetic autonomic neuropathy.

    Dupixent asthma initial therapy

    All criteria must be met, including one uncontrolled-asthma criterion.

    Asthma initial therapy: Eosinophils at least 150 cells/µL or oral corticosteroid-dependent asthma; ICS plus at least one additional controller; and uncontrolled asthma demonstrated by qualifying exacerbation, hospitalization, lung-function, or corticosteroid-taper criteria.

    Dupixent COPD initial therapy

    All criteria must be met.

    COPD initial therapy: Eosinophils at least 300 cells/µL; at least 3 months of combination therapy with at least two of LAMA, LABA, or ICS; and qualifying exacerbations or hospitalization in the prior 12 months.

    Dupixent continuation therapy

    Continuation requires prior treatment and an indication-specific beneficial response.

    Dupixent continuation: Patient completed the applicable prior Dupixent period and has the required indication-specific response and concurrent therapy; most listed indications require at least 6 months of prior therapy.

    Asthma

    All criteria must be met.

    Asthma: Eosinophils at least 150 cells/µL or oral corticosteroid-dependent asthma; ICS plus another controller; and at least one qualifying uncontrolled-asthma criterion.

    COPD

    All criteria must be met.

    COPD: Eosinophils at least 300 cells/µL; at least 3 months of at least two of LAMA, LABA, or ICS; and qualifying exacerbations or hospitalization in the prior year.

    Respiratory and allergic indications

    Meet the applicable indication-specific criteria.

    Respiratory and allergic indications: CRSwNP, eosinophilic esophagitis, or allergic fungal rhinosinusitis meeting the documented symptom, treatment, biopsy, imaging, weight, and surgical criteria.

    Dermatologic indications

    Meet the applicable disease-duration or treatment-history criterion.

    Dermatologic indications: Prurigo nodularis with pruritus for at least 6 weeks, or chronic spontaneous urticaria lasting more than 6 weeks despite a non-sedating H1 antihistamine.

    Elahere

    All criteria must be met.

    Elahere: Age at least 18 years, ovarian, fallopian tube, or primary peritoneal cancer diagnosis, and oncology prescriber or consultant.

    Elaprase

    One diagnostic confirmation pathway must be met.

    Elaprase: Deficient iduronate-2-sulfatase activity demonstrated by laboratory testing or a qualifying iduronate-2-sulfatase molecular genetic finding.

    Elrexfio

    All criteria must be met.

    Elrexfio: Multiple myeloma after at least four systemic regimens, including at least one drug from each required prior-treatment class.At least 4 systemic regimens; age >=18 years

    Emgality

    Meet the applicable headache criteria.

    Emgality: Migraine prevention with at least 4 migraine days per month and, for continuation, significant clinical benefit; or episodic cluster headache with one headache every other day to eight headaches per day.

    Emrelis

    All criteria must be met.

    Non-squamous NSCLC: Locally advanced or metastatic non-squamous NSCLC; c-Met overexpression of at least 50% of tumor cells with strong 3+ staining by an approved test; and at least one prior systemic therapy.

    Epidiolex

    Initial or continuation criteria must be met.

    Epidiolex: For the applicable seizure disorder, required prior or concomitant antiseizure therapy has been tried; continuation requires response.

    Epkinly

    At least one systemic therapy line is required.

    Epk​inly: Diffuse large B-cell, classic follicular, HIV-related B-cell lymphoma, or post-transplant lymphoproliferative disorder after one or more lines of systemic therapy.

    Epoetin alfa

    Meet the indication-specific anemia criteria.

    Epoetin alfa: Qualifying CKD, chemotherapy-associated, HIV/zidovudine, surgical, MDS, or myelofibrosis anemia with the applicable hemoglobin or erythropoietin threshold and treatment status.

    Erivedge

    Meet one qualifying pathway.

    Erivedge: Locally advanced BCC recurrent after surgery/radiation or unsuitable for both; metastatic or diffuse BCC; or medulloblastoma after chemotherapy with a sonic hedgehog pathway mutation.

    Epoetin alfa initial and continuation therapy

    Initial or continuation criteria must be met.

    Epoetin alfa: Initial therapy: Hb below 10 g/dL or serum erythropoietin at or below 500 mU/mL. Continuation: currently receiving an ESA and Hb at or below 12 g/dL.

    Erivedge coverage criteria

    Covered for qualifying indications.

    Erivedge: Qualifying locally advanced, metastatic, or diffuse basal cell carcinoma, or medulloblastoma meeting prior chemotherapy and sonic hedgehog mutation criteria.

    Erleada coverage criteria

    All FDA-approved indications require androgen deprivation.

    Erleada: Used with a GnRH analog or after bilateral orchiectomy.

    Erlotinib coverage criteria

    Meet one applicable indication pathway.

    Erlotinib: EGFR mutation-positive advanced/metastatic NSCLC; qualifying RCC with bevacizumab; chordoma after prior therapy; pancreatic cancer with gemcitabine; or advanced, recurrent, or metastatic vulvar cancer.

    Everolimus coverage criteria

    Meet the indication-specific requirements.

    Everolimus: Qualifying breast cancer, RCC, TSC-associated, thyroid, thymic, hematologic, neuroendocrine, sarcoma, meningioma, or other listed indication with required biomarker, combination, and prior-treatment criteria.

    Fabrazyme coverage criteria

    One diagnostic confirmation pathway must be met.

    Fabrazyme: Deficient alpha-galactosidase A activity in leukocytes or fibroblasts, or a pathogenic galactosidase alpha molecular variant.

    Fasenra initial therapy

    All criteria for the applicable indication must be met.

    Fasenra: Asthma with eosinophils at least 150 cells/µL, ICS plus another controller, and uncontrolled disease; active non-severe EGPA with eosinophils at least 150 cells/µL; or HES with FIP1L1-PDGFR-alpha-negative disease, no non-hematologic secondary cause, and eosinophils at least 1,000 cells/µL.

    Fintepla initial and continuation therapy

    Meet the applicable syndrome and antiseizure-treatment criteria.

    Fintepla: Dravet syndrome with at least two other antiseizure drugs or Epidiolex, clobazam, or Diacomit; Lennox-Gastaut syndrome with at least two other antiseizure drugs; continuation requires response.

    Fotivda coverage criteria

    All criteria must be met.

    Fotivda: Relapsed or stage IV renal cell carcinoma after at least two prior systemic regimens.

    Fruzaqla coverage criteria

    All criteria must be met.

    Fruzaqla: Advanced or metastatic colon, rectal, or appendiceal cancer; applicable pMMR/MSS or checkpoint-inhibitor and dMMR/MSI-H or POLE/POLD1 pathway; prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy plus anti-VEGF therapy; and any required RAS wild-type pathway treatment.

    Testosterone initial and continuation therapy

    Initial and continuation criteria apply to injectable testosterone.

    Initial hypogonadism therapy: Persistent androgen-deficiency signs and symptoms, two morning testosterone measurements on separate days, and both low by laboratory reference values.
    Continuation hypogonadism therapy: Persistent androgen-deficiency signs and symptoms and at least one low pretreatment testosterone level.

    Inlexzo

    All criteria must be met.

    Inlexzo: BCG-unresponsive disease, age at least 18 years, and oncologist or urologist prescriber or consultant.

    Inluriyo breast cancer

    All criteria must be met.

    Inluriyo: Recurrent, advanced, or metastatic HR-positive, HER2-negative, ESR1-mutated breast cancer; at least one prior endocrine therapy; and applicable postmenopausal, male, or ovarian-suppression/ablation status.

    Inlyta

    Meet one applicable indication pathway.

    Inlyta: Radioactive-iodine-refractory papillary or follicular thyroid carcinoma; oncocytic/Hurthle cell carcinoma; alveolar soft-part sarcoma with Keytruda; or thymic carcinoma after chemotherapy with Bavencio.

    Inpefa

    Meet one applicable indication.

    Inpefa: Heart failure; or type 2 diabetes with chronic kidney disease and at least one cardiovascular risk factor.

    Inqovi

    Both criteria must be met.

    Inqovi: AML and age at least 75 years or comorbidities precluding intensive induction therapy; use in combination with Venclexta.

    Inrebic

    A qualifying disease-related symptom is required.

    Inrebic: Covered myeloproliferative neoplasm indication and at least one disease-related symptom, such as fatigue, fever, night sweats, weight loss, abdominal discomfort, splenomegaly, thrombocytosis, or leukocytosis.

    Itovebi breast cancer

    All criteria must be met.

    Itovebi: Applicable menopausal or ovarian-suppression status; locally advanced or metastatic HR-positive, HER2-negative breast cancer; approved-test-detected PIK3CA mutation; progression or recurrence after adjuvant endocrine therapy; and combination use with palbociclib.

    Oral ivermectin

    Meet one qualifying infection or scabies circumstance.

    Oral ivermectin: Head, body, or pubic lice; or classic, treatment-resistant, crusted, topical-treatment-intolerant, or tablet-treated scabies.

    IVIG

    Coverage is subject to CMS benefit determination.

    IVIG: Use is for a medically accepted indication, with Part B versus Part D determination under CMS guidance when primary immunodeficiency is treated at home.

    Iwilfin

    All criteria must be met.

    Iwilfin: High-risk neuroblastoma, use to reduce relapse risk, and at least partial response to prior multimodality therapy including anti-GD2 immunotherapy.

    Jakafi and Jakafi XR

    Meet one applicable indication pathway.

    Jakafi and Jakafi XR: Covered ALL, GVHD, atypical CML, CMML-2, essential thrombocythemia, myeloid/lymphoid neoplasm, or T-cell lymphoma pathway with the required mutation, symptoms, combination, or prior therapy.

    Jaypirca

    Meet the applicable prior-treatment pathway.

    Jaypirca: Mantle-cell lymphoma after systemic chemotherapy or ineligibility plus prior BTK inhibitor; CLL/SLL after prior BTK inhibitor; or Richter transformation after chemotherapy or ineligibility with specified prior therapy.

    Jemperli

    Meet one applicable malignancy or biomarker pathway.

    Jemperli: Recurrent/advanced/metastatic endometrial cancer; dMMR/MSI-H solid tumor; qualifying dMMR/MSI-H or POLE/POLD1 small-bowel, colorectal, rectal, or appendiceal cancer; or qualifying single-agent anal carcinoma.

    Authorization, Documentation, and Denial Rules

    Prior Authorization

    Prior Authorization and Required Medical Information

    Prior authorization is required for ACTEMRA intravenous and subcutaneous products. Submit the diagnosis, concurrent medications, previous therapies tried, applicable age and prescriber information, and indication-specific clinical records.

    • Do not use concurrently with a biologic DMARD or targeted synthetic DMARD.
    • Do not approve ACTEMRA for treatment of COVID-19 in hospitalized patients under the non-D benefit.
    • Initial RA, PJIA, SJIA, or GCA therapy requires prescribing by or consultation with a rheumatologist; interstitial-lung-disease therapy requires pulmonology or rheumatology involvement.
    • RA and PJIA generally require a qualifying prior therapy or an exception such as heart failure or a previously treated lymphoproliferative disorder.
    • GCA requires prior systemic corticosteroid therapy or documented corticosteroid contraindication.
    • Authorization is generally through the end of the plan year.
    Documentation Required

    Required Medical Information and Diagnosis Documentation

    Submit complete diagnosis and supporting clinical documentation for all requested drugs, including laboratory results, pathology, genetic or molecular testing, prior-treatment history, concurrent medications, response to therapy, and benefit classification when applicable.

    • Documentation must support the requested indication, age, prescriber specialty, prerequisite therapy, and continuation response.
    • Part B versus Part D benefit determination is made during prior-authorization review when specified by the policy.
    • Requests lacking required medical information or documentation of the applicable criteria may be denied.
    Documentation Required

    Prolastin-C Documentation

    Prolastin-C requires documentation of alpha1-antitrypsin deficiency with emphysema or COPD, including baseline pretreatment clinical information. The patient must be 18 years or older; authorization is generally for one year.

    • Submit diagnosis documentation and the baseline pretreatment information requested by the plan.
    Prior Authorization

    Alunbrig ALK Status and Prerequisite Therapy

    Alunbrig requires prior authorization and documentation of ALK status. Coverage requires disease-specific documentation and, for newly treated advanced or metastatic NSCLC, a prior trial of Alecensa, Ensacove, or Lorbrena.

    • Document ALK rearrangement or fusion-positive disease using an approved test.
    • For IMT, document ALK-positive advanced, recurrent, metastatic, or inoperable disease.
    • For peripheral T-cell lymphoma, document ALK-positive anaplastic large-cell lymphoma.
    • Submit prior ALK-inhibitor therapy when required.
    Prior Authorization

    Anktiva Diagnosis Documentation

    Anktiva requires prior authorization for adults with high-risk BCG-unresponsive non-muscle-invasive bladder cancer. Submit diagnosis documentation confirming carcinoma in situ and use in combination with BCG.

    • Initial therapy requires all of the following: high-risk BCG-unresponsive disease, carcinoma in situ, and combination use with BCG.
    • Initial requests are generally authorized for six months and maintenance requests for three months.
    • Prescribing or consultation by an oncologist or urologist is required.
    Prior Authorization

    IV Antibiotic Prior Authorization

    Prior authorization is required for the listed intravenous antibiotics. Submit the diagnosis and clinical rationale for the requested agent; authorization is generally limited to three months.

    • Affected products include the listed intravenous antibacterial agents such as levofloxacin, linezolid, meropenem, metronidazole, nafcillin, oxacillin, penicillin G, streptomycin, trimethoprim-sulfamethoxazole, ceftazidime, ceftaroline, tigecycline, tobramycin, and telavancin.
    • Document the infection being treated and the requested treatment course.
    Prior Authorization

    IV Antifungal Prior Authorization

    Prior authorization is required for intravenous antifungal therapy. Submit diagnosis documentation and the requested treatment course; authorization is generally limited to three months.

    • Affected products include intravenous voriconazole and voriconazole-HBCD.
    • Document the fungal infection and medical necessity for intravenous treatment.
    Denial Risk

    Arcalyst Exclusions and DIRA Requirements

    Arcalyst requires prior authorization and must not be used concurrently with biologic therapy. Submit indication-specific documentation and the required specialist information.

    • For DIRA, document weight of at least 10 kg, biallelic pathogenic IL1RN variants on genetic testing, and clinical benefit from subcutaneous anakinra.
    • For recurrent pericarditis, document recurrent disease; cardiology or rheumatology involvement is required.
    • Continuation requires a positive response to therapy.
    • For CAPS, initial therapy is restricted to patients at least 12 years old and requires the applicable specialist.
    Prior Authorization

    Arikayce Diagnosis and Treatment History

    Arikayce requires documentation of MAC lung disease and treatment history. Initial therapy requires positive MAC sputum culture, an amikacin-susceptible isolate, and combination use with a background multidrug regimen.

    • Document the diagnosis, positive sputum culture, susceptibility results, and prior medication history.
    • The background regimen should include a macrolide, ethambutol, and a rifamycin unless the record supports another regimen.
    • Continuation requires combination use with the background regimen and either persistently negative cultures not yet achieved or negative cultures for less than 12 months.
    • Initial therapy is for adults and requires pulmonology, infectious-disease, or MAC-lung specialist involvement.

    Unsupported block type: prior_auth

    Unsupported block type: prior_auth

    Unsupported block type: prior_auth

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: prior_auth

    Prior Authorization

    Additional Indication and Prerequisite Rules

    The following additional prior-authorization rules apply: age, specialist, indication, prior-treatment, combination-therapy, exclusion, and benefit-classification criteria must be satisfied and documented before approval.

    • Alosetron: patient must be 18 years or older.
    • Asparlas: patient must be 1 month through 21 years of age.
    • Augtyro: submit diagnosis and ROS1 or NTRK molecular results and document disease extent.
    • Avmapki-Fakzynja: document recurrent low-grade serous ovarian, fallopian-tube, or primary-peritoneal cancer, KRAS mutation, and prior systemic therapy.
    • Avonex and Betaseron/Extavia: document relapsing MS and no concurrent MS disease-modifying therapy.
    • Ayvakit: document the qualifying PDGFRA mutation, GIST prior therapies, or systemic-mastocytosis criteria.
    • Balversa: document FGFR alteration, disease, and required prior platinum, chemotherapy, checkpoint inhibitor, or combination therapy.
    • Blenrep: document prior proteasome-inhibitor and immunomodulatory-drug classes and required combination therapy.
    • Droxidopa: document symptomatic neurogenic orthostatic hypotension, qualifying autonomic disorder, and prior medication history.
    • Erivedge: document qualifying basal-cell or CNS cancer, prior chemotherapy, prior local therapy or ineligibility for surgery/radiation, and applicable mutation.
    • Erleada: document concurrent GnRH-analog therapy or bilateral orchiectomy.
    • Everolimus: document prior endocrine or systemic therapy, required combination, and absence of progression on everolimus.

    Unsupported block type: denial_risk

    Note

    Specialty Drug Authorization Duration

    Specialty-drug authorization is generally limited to the duration stated in the product criteria, commonly one year, with shorter initial or induction periods for selected products. Submit continuation documentation before expiration.

    • Document beneficial clinical response for continuation therapy.
    • Initial and continuation durations may differ for Anktiva, Arcalyst, Camzyos, Dupixent, Fasenra, Doptelet, and other products.
    • Authorization does not replace required medical-necessity review or benefit determination.

    Initial Therapy Decision Criteria

    Rheumatoid arthritis initial therapy

    Initial therapy is covered when either pathway is met.

    Rheumatoid arthritis: Tried one qualifying drug: Enbrel, preferred adalimumab product, Rinvoq, or tofacitinib/tofacitinib XR; specified alternatives also count. Alternatively, the patient has heart failure or a previously treated lymphoproliferative disorder.

    PJIA initial therapy

    Initial therapy is covered when either pathway is met.

    PJIA: Tried one qualifying drug: Enbrel, Rinvoq, tofacitinib, or preferred adalimumab product; specified alternatives also count. Alternatively, the patient has heart failure or a previously treated lymphoproliferative disorder.

    Other initial therapy criteria

    Meet the applicable indication criteria.

    Other initial indications: Systemic-onset JIA; giant cell arteritis with systemic corticosteroid trial, current use, or contraindication; or systemic-sclerosis-associated interstitial lung disease with elevated acute phase reactants and high-resolution CT confirmation.

    Arcalyst initial therapy

    Meet the applicable indication pathway.

    Arcalyst: DIRA with weight at least 10 kg, biallelic pathogenic IL1RN variants, and anakinra benefit; recurrent pericarditis; or CAPS.

    Arikayce initial therapy

    All criteria must be met.

    Arikayce: Positive MAC sputum culture, amikacin-susceptible isolate, and use with a background multidrug regimen.

    Avmapki-fakzynja

    All criteria must be met.

    Avmapki-fakzynja: Recurrent low-grade serous ovarian, fallopian tube, or primary peritoneal cancer, KRAS mutation, and at least one prior systemic therapy.

    Avonex

    All criteria must be met.

    Avonex: Relapsing MS and neurologist or MS specialist prescribing or consultation.

    Ayvakit

    Meet the applicable disease criteria.

    Ayvakit: Qualifying GIST, PDGFRA D842V-positive myeloid/lymphoid neoplasm with eosinophilia, or systemic mastocytosis with platelet count at least 50,000/mcL and qualifying subtype.

    Balversa

    Meet the applicable disease and FGFR criteria.

    Balversa: Qualifying FGFR-altered cancer with required disease stage, prior therapy, and treatment setting.

    Benlysta

    Meet the applicable SLE or lupus nephritis criteria.

    Benlysta: Biopsy-confirmed lupus nephritis with concurrent immunosuppressive therapy, or autoantibody-positive SLE with concurrent standard therapy; initial age at least 5 years.

    Besremi

    All criteria must be met.

    Besremi: Qualifying diagnosis, age at least 18 years, and oncologist or hematologist prescribing or consultation.

    Bexarotene

    A qualifying indication must be documented.

    Bexarotene: FDA-approved indication or qualifying cutaneous or hematologic lymphoma indication; topical therapy must meet its disease-specific criteria.

    Bizengri

    Meet the applicable NRG1-positive cancer criteria.

    Bizengri: Advanced, unresectable, or metastatic NRG1 gene-fusion-positive cholangiocarcinoma, NSCLC, or pancreatic adenocarcinoma; NSCLC and pancreatic cancer require at least one prior systemic regimen.

    Blenrep

    All criteria must be met.

    Blenrep: Prior proteasome inhibitor and immunomodulatory drug exposure, and planned combination with bortezomib and dexamethasone.

    Boniva Injection

    Postmenopausal osteoporosis plus one qualifying criterion is required.

    Boniva Injection: Postmenopausal osteoporosis and qualifying bone-density, fracture, prior-treatment, intolerance, or oral-therapy limitation criterion.

    Bosentan or Ambrisentan

    Meet the applicable PAH or CTEPH criteria.

    Bosentan or Ambrisentan: WHO Group 1 PAH confirmed by right-heart catheterization, or CTEPH treated with bosentan after the specified Adempas prerequisite or current bosentan use.

    Bosulif

    Meet the applicable leukemia criteria.

    Bosulif: Ph-positive/BCR::ABL1-positive CML; Ph-positive ALL after another TKI; or qualifying myeloid/lymphoid neoplasm with eosinophilia.

    Bosentan/ambrisentan initial therapy

    All applicable initial criteria must be met.

    Bosentan/ambrisentan: WHO Group 1 PAH confirmed by right-heart catheterization and specialist prescribing or consultation; for CTEPH treated with bosentan, the required Adempas condition also applies.

    Camzyos initial therapy

    All criteria must be met.

    Camzyos: Symptomatic obstructive HCM, NYHA class II or III heart failure, specified LV hypertrophy, and peak LV outflow tract gradient at least 50 mmHg.

    Deferasirox initial therapy

    Meet one initial pathway.

    Deferasirox: Qualifying iron-overload condition with ferritin greater than 1,000 mcg/L, or non-transfusion-dependent thalassemia with ferritin greater than 300 mcg/L before therapy.

    Diacomit initial therapy

    All criteria must be met.

    Diacomit: Age at least 6 months, Dravet syndrome, and clobazam use or inability to take clobazam because of adverse events.

    Droxidopa initial therapy

    All criteria must be met.

    Droxidopa: Age at least 18 years and symptomatic NOH due to an eligible autonomic disorder.

    Dupixent initial therapy

    Meet one applicable indication pathway and its age and prescriber requirements.

    Dupixent: Atopic dermatitis, asthma, COPD, CRSwNP, EoE, prurigo nodularis, CSU, bullous pemphigoid, or allergic fungal rhinosinusitis meeting the applicable criteria.

    Initial specialty therapy

    All applicable age, prescriber, and disease-specific criteria must be met.

    Initial specialty therapy: Meet the clinical criteria, age restriction, and specialist prescriber or consultation requirement for the requested indication.

    Enbrel

    Prerequisite therapy is required except for GVHD.

    Enbrel: For specified inflammatory indications, try a preferred or non-preferred adalimumab product; for Behcet disease, try a conventional therapy; GVHD does not require the stated prerequisite.

    Endari and Ensacove

    Meet the applicable age and prescriber criteria.

    Endari: Age at least 5 years and sickle-cell specialist prescribing or consultation.
    Ensacove: Age at least 18 years and an FDA-approved indication.

    Fasenra initial therapy

    Meet all criteria for the applicable indication.

    Fasenra: Asthma with eosinophilia, ICS plus controller, and uncontrolled disease; active non-severe EGPA with eosinophilia; or qualifying HES.

    Fintepla initial therapy

    Meet the applicable syndrome and treatment-history criteria.

    Fintepla: Dravet syndrome with qualifying antiseizure treatment or specified Epidiolex, clobazam, or Diacomit; or Lennox-Gastaut syndrome with at least two antiseizure drugs.

    Testosterone initial therapy

    All criteria must be met for hypogonadism initial therapy.

    Testosterone: Persistent androgen-deficiency signs and symptoms, two morning testosterone measurements on separate days, and both low by laboratory reference values.

    Continuation Therapy Decision Criteria

    Arcalyst continuation

    Continuation requires a positive response.

    Arcalyst: Patient had a positive response to therapy.

    Arikayce continuation

    Both criteria must be met.

    Arikayce is used with a background multidrug regimen and sputum cultures are either not negative or have been negative for less than 12 months.

    Benlysta continuation

    Both criteria must be met for lupus nephritis continuation.

    Benlysta: Concurrent immunosuppressive regimen and response to Benlysta subcutaneous or intravenous therapy.

    Benlysta IV continuation

    Continuation criteria remain satisfied.

    Benlysta IV: Applicable SLE or lupus nephritis continuation criteria remain satisfied.1 year continuation authorization

    Cinryze continuation

    Both criteria must be met.

    Cinryze: Type I or II HAE and favorable clinical response to Cinryze prophylaxis compared with baseline.

    Camzyos continuation

    All criteria must be met.

    Camzyos: At least 8 months established therapy; current or prior obstructive HCM symptoms and NYHA class II or III heart failure; current LVEF at least 50%; and objective benefit or symptom stabilization/improvement.

    Deferasirox continuation

    Continuation requires benefit.

    Deferasirox: Prescribing physician confirms that the patient is benefiting from deferasirox.

    Deferiprone continuation

    Continuation requires benefit.

    Deferiprone: Patient is benefiting from deferiprone therapy.

    Diacomit continuation

    Continuation requires response.

    Diacomit: Patient is responding to Diacomit therapy.

    Dupixent continuation

    Continuation requires prior treatment and an indication-specific response.

    Dupixent: Patient completed the applicable prior treatment period and has the required beneficial response and concurrent therapy for the indication.

    Preceding specialty indications

    Continuation is authorized when applicable criteria remain satisfied.

    Preceding specialty indications: Patient continues to meet the applicable indication-specific criteria and demonstrates ongoing clinical benefit where required.

    Continuation response

    Continuation requires clinical benefit or response.

    Continuation response: Emgality: significant clinical benefit such as fewer migraine days; or Epidiolex: response to therapy.

    Fasenra continuation

    Continuation is authorized for 12 months for asthma, HES, and EGPA.

    Fasenra: Continuation criteria apply; detailed continuation criteria are not provided in the supplied policy window.

    Fintepla continuation

    Continuation requires response.

    Fintepla: Patient is responding to therapy.

    Testosterone continuation therapy

    All continuation criteria must be met.

    Testosterone: Persistent signs and symptoms of androgen deficiency and at least one low pretreatment serum testosterone level.

    Prerequisite and Step-Therapy Requirements

    StepProduct/indicationPrior-therapy requirement
    1Rheumatoid arthritisTry Enbrel, a preferred adalimumab product, Rinvoq, or tofacitinib/tofacitinib XR. Trials of Cimzia, Kevzara, infliximab, golimumab, Orencia, or a non-preferred adalimumab product also count. Heart failure or a previously treated lymphoproliferative disorder is an alternative.
    StepProduct/indicationPrior-therapy requirement
    1Polyarticular juvenile idiopathic arthritisTry Enbrel, Rinvoq, tofacitinib, or a preferred adalimumab product. Trials of Kevzara, infliximab, Orencia, or a non-preferred adalimumab product also count. Heart failure or a previously treated lymphoproliferative disorder is an alternative.
    StepProduct/indicationPrior-therapy requirement
    1Giant cell arteritisTry or be currently taking a systemic corticosteroid, or document that corticosteroids are contraindicated.
    StepProduct/indicationPrior-therapy requirement
    1Alunbrig — ALK-positive advanced or metastatic NSCLC; new to therapyTry Alecensa, Ensacove, or Lorbrena before approval.
    StepProduct/indicationPrior-therapy requirement
    1Arcalyst — DIRAPrior anakinra subcutaneous injection therapy with documented clinical benefit.
    StepProduct/indicationPrior-therapy requirement
    1Avmapki-Fakzynja — recurrent low-grade serous ovarian, fallopian tube, or primary peritoneal cancerAt least one prior systemic therapy; examples include paclitaxel, carboplatin, bevacizumab, letrozole, anastrozole, or exemestane.
    StepProduct/indicationPrior-therapy requirement
    1Avmapki-fakzynja — recurrent low-grade serous ovarian, fallopian tube, or primary peritoneal cancerTrial of at least one systemic therapy is required.
    StepProduct/indicationPrior-therapy requirement
    1Ayvakit — GISTTry two listed therapies: imatinib, sunitinib, dasatinib, regorafenib, or ripretinib, unless the tumor has a PDGFRA exon 18 mutation.
    StepProduct/indicationPrior-therapy requirement
    1BlenrepPrior exposure to at least one proteasome inhibitor and one immunomodulatory drug.
    StepProduct/indicationPrior-therapy requirement
    1Bosentan — CTEPHTry Adempas, have an Adempas contraindication, or be currently receiving bosentan for CTEPH.
    StepProduct/indicationPrior-therapy requirement
    1Bosulif — Philadelphia chromosome-positive ALLPrior treatment with at least one other tyrosine kinase inhibitor.
    StepProduct/indicationPrior-therapy requirement
    1Bosentan — CTEPHTry Adempas, have a contraindication to Adempas, or already be receiving bosentan for CTEPH.
    StepProduct/indicationPrior-therapy requirement
    1Bosulif — Philadelphia chromosome-positive ALLPrior treatment with at least one other tyrosine kinase inhibitor.
    StepProduct/indicationPrior-therapy requirement
    1BrukinsaIndication-specific prior systemic regimens or specified combination therapy are required. Follicular lymphoma requires at least two prior systemic regimens; mantle cell, marginal zone, and primary CNS lymphoma generally require at least one.
    StepProduct/indicationPrior-therapy requirement
    1CabometyxIndication-specific prior therapy is required, including prior systemic therapy for hepatocellular, bone, endometrial, thyroid, GIST, or RET-positive NSCLC indications as specified.
    StepProduct/indicationPrior-therapy requirement
    1CalquenceAt least one prior systemic regimen for mantle cell lymphoma, marginal zone lymphoma, or Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma, unless the stated mantle cell lymphoma exception applies.
    StepProduct/indicationPrior-therapy requirement
    1Doptelet tablets — chronic liver disease thrombocytopeniaTry another therapy, such as systemic corticosteroids, IVIG, anti-D immunoglobulin, eltrombopag, romiplostim, fostamatinib, or rituximab, or undergo splenectomy.
    StepProduct/indicationPrior-therapy requirement
    1Dupixent — COPDReceive at least 3 months of combination therapy with at least two of LAMA, LABA, or ICS before initiation.
    StepProduct/indicationPrior-therapy requirement
    1Dupixent — asthmaUse an inhaled corticosteroid with at least one additional asthma controller or maintenance medication.
    StepProduct/indicationPrior-therapy requirement
    1Enbrel — initial therapyFor RA, JIA/JRA, ankylosing spondylitis, plaque psoriasis, or psoriatic arthritis, try one preferred or non-preferred adalimumab product. For Behcet disease, try at least one conventional therapy. No stated prerequisite applies for GVHD.
    StepProduct/indicationPrior-therapy requirement
    1Epidiolex — initial therapyTry or concomitantly receive at least two other antiseizure drugs. For Dravet syndrome, Diacomit, clobazam, or Fintepla may alternatively satisfy the requirement.
    StepProduct/indicationPrior-therapy requirement
    1Elrexfio — multiple myelomaTry at least four systemic regimens, including at least one drug from each required prior-treatment class.
    StepProduct/indicationPrior-therapy requirement
    1Erivedge — locally advanced basal cell carcinoma, new startsRecurrent disease after surgery or radiation, or the patient is not a candidate for both surgery and radiation.
    StepProduct/indicationPrior-therapy requirement
    1Fintepla — initial therapyTry or concomitantly receive at least two other antiseizure drugs. For Dravet syndrome, Epidiolex, clobazam, or Diacomit may alternatively satisfy the requirement.
    StepProduct/indicationPrior-therapy requirement
    1Fotivda — relapsed or stage IV RCCAt least two prior systemic regimens.
    StepProduct/indicationPrior-therapy requirement
    1Fruzaqla — advanced or metastatic colon, rectal, or appendiceal cancerPrior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy plus an anti-VEGF agent; applicable checkpoint-inhibitor pathway requirements also apply.
    StepProduct/indicationPrerequisite requirement
    1Testosterone — female-to-male gender reassignment/endocrinologic masculinizationPrescribing by or consultation with an endocrinologist or a physician specializing in transgender patient treatment.
    StepProduct/indicationPrior-therapy requirement
    1Inluriyo — breast cancerTried at least one endocrine therapy, such as fulvestrant, anastrozole, exemestane, letrozole, or tamoxifen.
    StepProduct/indicationPrior-therapy requirement
    1InlytaFor differentiated thyroid carcinoma, disease must be refractory to radioactive iodine where applicable; thymic carcinoma requires at least one prior chemotherapy regimen.
    StepProduct/indicationPrerequisite requirement
    1Inqovi — AMLPatient is at least 75 years old or has comorbidities precluding intensive induction therapy, and Inqovi is used in combination with Venclexta.
    StepProduct/indicationPrior-therapy requirement
    1Jakafi or Jakafi XRIndication-specific prior treatment may include hydroxyurea, peginterferon alfa-2a, anagrelide, a conventional systemic treatment, a systemic corticosteroid, or other specified therapy.
    StepProduct/indicationPrior-therapy requirement
    1JaypircaMantle cell lymphoma requires prior systemic chemotherapy or ineligibility for it plus a prior BTK inhibitor. CLL/SLL requires a prior BTK inhibitor. Richter transformation requires prior chemotherapy or ineligibility for a systemic regimen.

    Quantity and Duration Limits

    Ivermectin oral tablet quantity limit
    MedicationIvermectin oral tablet 3 mg and 6 mg
    Coverage duration30 days
    Covered conditionsPediculosis and qualifying scabies, including classic, treatment-resistant, crusted, or topical-treatment-intolerant scabies
    Prerequisite therapyYes

    Preferred Biosimilar Prerequisites

    Note

    Use a preferred adalimumab product when required

    These products are identified as preferred adalimumab products for Enbrel prerequisite therapy. A trial of a non-preferred adalimumab product also counts.

    • Preferred products: Hadlima and Simlandi.
    Policy Summary
    PayerCareSource
    PolicyActemra intravenous and subcutaneous coverage
    Policy CodePolicy 4588458
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization for Actemra intravenous, Actemra ACTPEN, or Actemra subcutaneous products and include the diagnosis, concurrent medications, and previous drugs tried.
    SourceLink
    On This Page
    Product-Specific Coverage CriteriaAuthorization, Documentation, and Denial RulesInitial Therapy Decision CriteriaContinuation Therapy Decision CriteriaPrerequisite and Step-Therapy RequirementsQuantity and Duration LimitsPreferred Biosimilar Prerequisites
  1. Inlexzo, Inluriyo, Inlyta, Inqovi, Itovebi, Ivermectin, Iwilfin, Jakafi, and Jaypirca: submit diagnosis, required prior therapy, molecular or combination-therapy evidence, and benefit classification when applicable.